Icobrain dm
Artificial Intelligence (AI) is revolutionizing the healthcare sector globally with pioneering applications in medical imaging and diagnosis. Affidea, investing in methods and procedures aimed at safeguarding patient safety while ensuring optimal medical outcomes, utilizes AI-based tools in daily clinical practice, significantly enhancing patient care and treatment accuracy.
Affidea Greece places Artificial Intelligence at the service of doctors for brain MRI, aiming for the timely and accurate differential diagnosis of dementia and Alzheimer’s disease. The icobrain dm software, now applied in Affidea diagnostic centers, allows for faster and more accurate diagnoses for personalized treatment. Specifically, icobrain dm provides visual and quantitative comparison with a broad database, adjusted for the examinee's gender and age. With specific data tailored to the patient’s profile, it leads to more informed and quicker care decisions.
To understand the importance of Artificial Intelligence in diagnosis and choosing the right treatment protocol for the patient without losing valuable time, we need to consider the recent data:
On average, it takes 3 years from the onset of initial symptoms to the diagnosis of Alzheimer’s disease.
60% of Alzheimer’s patients are underdiagnosed.
80% of patients are diagnosed late.
50% of primary care physicians are not familiar with Alzheimer’s disease
The integration of Artificial Intelligence is feasible at Affidea as the diagnostic centers are equipped with high-tech MRI scanners that gather personalized data from each examinee, ensuring excellent imaging results in a very short time.
Artificial Intelligence at Affidea redefines patient care with tools for accurate diagnosis and operational efficiency. This development marks a significant leap towards the future of precision medicine, ensuring that each patient receives the best possible care tailored to their unique needs.
